Cell viability assays under radiofrequency application modulated by nanomaterials

In this keynote talk, it will be explored the use of the Hill model to assess the Benchmark dose (BMD), the lethal dose 50 (LD50), the cooperativity (E) and the dissociation constant (K) while analyzing cell viability data using nanomaterials. The presentation is addressed to discuss the antitumor potential while combining radiofrequency (RF) therapy in and selected nanomaterials. In particular, it will be discussed the use of nanocomposites, for instance comprising graphene oxide (GO) surface functionalized with polyethyleneimine (PEI) and decorated with gold nanoparticles (GO-PEI-Au). Data collected from the cell viability assays using different tumor cell lines (e.g. LLC-WRC-256 and B16-F10) will be presented and discussed. The findings will demonstrate that while the tested nanocomposite (e.g. GO-PEI-Au) may be biocompatible against different cancer cell lines in the absence of radiofrequency (nRF), the application of radiofrequency (RF) enhances the cell toxicity by orders of magnitude, pointing to prospective studies with the tested cell lines using tumor animal models.

Professor Paulo César De Morais (H60), PhD, was full Professor of Physics at the University of Brasilia (UnB) – Brazil up to 2013. Appointed as UnB’s (Brazil) Emeritus Professor (2014); Visiting Professor at the Huazhong University of Science and Technology (HUST) – China (2012-2015); Distinguished Professor at the Anhui University (AHU) – China (2016-2019); Full Professor at the Catholic University of Brasília (CUB) – Brazil (2018); CNPq-1A Research Fellow since 2010; 2007 Master Research Prize from UnB. He held two-years (1987-1988) post-doc position with Bell Communications Research, New Jersey – USA and received his Doctoral degree in Solid State Physics (1986) from the Federal University of Minas Gerais (UFMG) – Brazil. With more than 13,000 citations, He has published more than 500 papers (Web of Science), delivered more than 200 international invited talks, and filed more than 15 patents.